zh-twzhen
zh-twzhen

News-Outstanding Corporate Governance Evaluation Results for the Microbio Group Microbio and Oneness Rank among Top 5% in the Corporate Governance Evaluation for Four Consecutive years; Diamond Biofund Enters Top 5% on Its First Evaluation

2021

Date

Title

2021-08-06

A Chinese patent on the producing of recombinant glycoproteins with modified glycosylation was granted.

>
2021-07-21

Oneness Biotech Co., LTD. receives a Russian patent titled”TOPICAL FORMULATION FOR PROMOTING WOUND HEALING” on Fespixon cream (Research code:ON101).

>
2021-06-23

Oneness announces the information about the investor’s conference of 2021 Q2.

>
2021-06-16

Oneness Bio will hold the launch event and the medical symposium of Fespixon, the new drug for treating DFUs

>
2021-06-10

Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A.

>
2021-06-08

An IND was submitted to US FDA for a phase II clinical trial of FB704A, an anti-IL6 mAb developed by Oneness, for treating severe COVID-19.

>
2021-06-03

The Phase 3 international MRCT study results of the diabetic foot ulcer new drug, Fespixon have been accepted for oral presentation at the 57th EASD Annual Meeting

>
2021-06-01

A Chinese patent titled “USE OF FLAVOIDS IN MANUFACTURING COMPOSITIONS FOR WOUND HEALING.” has been granted.

>
2021-05-21

The annual shareholders’ meeting will be postponed in accordance with the instructions of FSC.

>
2021-05-14

A Chinese patent titled ”Use of Plectranthus amboinicus extract in manufacturing compositions for anA Taiwan patent titled “Biomarkers for lung cancer stem cells” has been granted

>
2021-05-11

A Chinese patent titled ”Use of Plectranthus amboinicus extract in manufacturing compositions for anti-microbial effect”has been granted.

>
2021-05-06

A Taiwan patent titled “Method for treating cancer using cd14 antagonists” has been granted.

>
2021-04-19

Oneness received approval by TFDA on the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma.

>
2021-04-12

Oneness announces that Nanchou manufacturing site has been GMP and GDP certified by MOHW

>
2021-04-07

Oneness has submitted the phase 2 clinical trial application for FB704A, a fully-human anti-IL6 antibody new drug, in severe asthma to TFDA via fast track.

>